MedX Health Corp. Announces Board and Executive Changes

MedX Health Corp. (MedX) announces the following changes to its board and executive team, effective immediately. Scott Spearn, who joined the company as president in April, is taking on the additional role of CEO and is joining the Board of Directors. Former CEO Rob von der Porten has been appointed board chairman in place of Gary Van Nest, who has retired but remains as a director.
 
“With the recent launch of our DermSecure telemedicine platform and anticipating a global roll-out of this leading product, the transition of Scott’s role to CEO represents a natural evolution at MedX,” noted von der Porten. “Scott’s experience in building sales organizations and developing international markets in the medical device field will help accelerate our growth from our SIAscopy technology and our therapeutic and dental laser products.”
 
Gary Van Nest noted, “On behalf of the board, we want to thank Rob von der Porten for his leadership during challenging times over the past few years and developing with the MedX team solid product roadmaps such as the delivery of DermSecure.”

Spearn is a seasoned medical device executive with nearly 30 years of developing sustainable, trusted relationships with key opinion leaders, strategic partners, and industry influencers. Before joining MedX, Spearn held a number of senior executive roles at a multi-national medical device company where he substantially grew revenues across several business divisions.

“I am excited to be taking on the CEO role, leading a team of hard-working people. MedX is a great Canadian company with products and robust technology that is making a big difference in the health of people’s lives around the world,” said Spearn.
 
The company has granted 1 million share options to the incoming CEO, the options having an exercise price of $0.16, exercisable for a period of five years, and vesting over a one-year period.
 
MedX, headquartered in Mississauga, Ontario, is a medical device and software company focused on skin cancer with its DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS, SIMSYS, and MoleMate, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS, SIMSYS, and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, U.S. Food and Drug Administration, ARTG and CE cleared for use in Canada, the United States, Australia, New Zealand, the European Union, and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain.